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 Managing acute intracerebral haemorrhage is a  challenging 
task for physicians. Evidence shows that outcome can be 
 improved with admission to an acute stroke unit and  active 
care, including urgent reversal of anticoagulant  effects and, 
potentially, intensive blood pressure reduction.  Nevertheless, 
many management issues remain  controversial,  including 
the use of haemostatic therapy, selection of patients 
for  neurosurgery and neurocritical care, the extent of 
 investigations for underlying causes and the benefi t versus 
risk of restarting antithrombotic therapy after an episode of 
intracerebral haemorrhage. 
 Introduction 
 Spontaneous intracerebral haemorrhage (sICH) is a common 
medical emergency with a mortality rate of 40% at 1 month. 1 
Although advancement has been made in the treatment of 
ischaemic stroke, research into the management of spontaneous 
intracerebral haemorrhage has lagged behind. Nevertheless, 
recent evidence provides some insight into the optimal 
management of patients with sICH, which can improve 
outcome. 
 Neuroimaging for sICH 
 Apart from diagnosing sICH, the main aims of neuroimaging 
are to detect complications, such as haematoma expansion 
(Fig  1 ), intraventricular extension, hydrocephalus, cerebral 
oedema and mass effect. In addition, neuroimaging is crucial 
to identify the underlying aetiology. Urgent computerised 
(CT) scan and magnetic resonance imaging (MRI) are equally 
effective in diagnosing sICH. CT angiography is often done 
in a research setting to look for contrast extravasation or 
positive spot sign, which predicts haematoma expansion. 2 
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 Management of acute intracerebral haemorrhage – 
an update 
CT angiography-positive spot sign has a sensitivity of 63% 
and specificity of 90% in predicting haematoma expansion. 2 
Predicting haematoma expansion could be useful in stratifying 
patients at risk of deterioration. 
 It was previously thought that investigations for an 
underlying structural or vascular lesion should be reserved 
for patients aged <45 years, with normotension and lobar 
haemorrhage. 3 This assumption is unreliable as angiographic 
studies showed that up to 20% of patients with sICH have 
underlying vascular abnormalities; many of these patients 
were elderly and hypertensive with deep-seated haematomas. 4 
Hence, all patients should be considered for non-invasive 
vascular imaging (CT angiography or magnetic resonance 
angiography) and structural imaging (MRI). These should be 
performed as early as possible to enable early interventions. 
Invasive digital subtraction angiography should be reserved 
for patients where the suspicion of vascular anomalies remains 
high despite negative non-invasive imaging. 5 
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 Key points 
 
 All patients should be actively treated in an acute stroke unit 
or intensive care unit with avoidance of early do not attempt 
resuscitation orders 
 In patients presenting within 6 hours of onset, lowering systolic 
blood pressure to <140 mmHg within 1 hour of admission is 
safe and may be beneficial 
 Patients taking anticoagulation should receive urgent reversal 
with the appropriate antidote 
 Patients with superficial haematoma and Glasgow Coma Scale 
score of 9–12 may benefit from neurosurgery 
 All patients with spontaneous intracerebral haemorrhage 
should be considered for investigation of underlying aetiology 
using structural and vascular neuroimaging 
 KEYWORDS: Antithrombotic, blood pressure, intracerebral 
haemorrhage, management, neurosurgery, stroke ■ 
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 Acute medical management 
 The benefits of the acute stroke unit are well established. 
Admission to an acute stroke unit improves outcome in 
terms of death and dependency (Odds ratio 0.79, 95% 
confidence interval (CI) 0.68–0.90; p = 0.0007). 6 Neurological 
complications of sICH – including haematoma expansion, 
peri-haematomal oedema, intraventricular extension of 
haemorrhage, hydrocephalus, seizures and non-neurological 
complications, such as aspiration pneumonia and venous 
thromboembolism – all lead to poor prognosis. 7,8 Therefore, 
the aim of acute management is to detect and prevent 
these complications. Importantly, an early do not attempt 
resuscitation (DNAR) order should be avoided in the first few 
days since it limits optimal medical care and results in poor 
outcome. 9,10 Table  1 summarises the recommendations in 
management of sICH. 
 Blood pressure control 
 Very elevated blood pressure (BP) increases the risk of 
haematoma expansion, leading to a poor prognosis in 
sICH. 11 Conversely, there is a concern that lowering BP 
acutely reduces cerebral perfusion pressure and leads to 
peri-haematomal ischaemia and infarction. However, recent 
trials have demonstrated the safety of intensive BP reduction. 
INTERACT-2 (Intensive Blood Pressure Reduction in Acute 
Cerebral Hemorrhage Trial 2), involving 2,839 patients, 
showed that those with intensive BP reduction did not have 
an increased rate of ischaemic events. 12 Similarly, the ATACH 
(Antihypertensive Treatment of Acute Cerebral Hemorrhage) 
study demonstrated safety of intensive blood pressure 
reduction in sICH. 13 Additionally, a subgroup analysis of ENOS 
(Efficacy of Nitric Oxide in Stroke) trial patients with sICH 
presenting within 6 hours showed benefit of BP reduction with 
glyceryl trinitrate on functional outcome. 14 A meta-analysis 
showed that intensive blood pressure reduction is safe, with 
a non-significant tendency towards a favourable outcome, 
which may be mediated through attenuation of haematoma 
expansion. 15 Recent guidelines suggest lowering BP to a systolic 
of 140 mmHg within 1 hour in those presenting within 6 hours 
of symptom onset is safe and may have a beneficial effect on 
functional outcome. 16–18 
 The most recent development of BP treatment in sICH 
is the ATACH-2 trial, which was stopped early in view of 
futility. Although there was no significant difference in 
death or dependency between the intensive and guideline 
treatment groups, there was a non-significant reduction in 
haematoma expansion in the intensive treatment arm. In 
addition, there were higher renal adverse events in those 
treated with intensive BP reduction. 19 There are several 
potential reasons why ATACH-2 had different findings 
compared to previous trials. Patients in the trial received 
intravenous antihypertensive medication pre-randomisation 
to ensure compliance with guidelines. Further, the blood 
pressure reduction was much larger than seen in previous 
trials – from a baseline systolic BP (SBP) of approximately 
200 mmHg, the intensive arm achieved a mean minimum SBP 
of 129 mm Hg, while the standard treatment arm attained a 
mean minimum SBP of 141 mm Hg. In contrast, the baseline 
BP was approximately 179 mm Hg in INTERACT-2, with the 
intensive and standard treatment groups achieving a SBP of 
150 mmHg and 164 mmHg at 1 hour post randomisation, 
respectively. These results suggest that the degree of BP 
reduction in the standard arm of ATACH-2 is similar to the 
intensive arm of INTERACT-2. In addition, all patients in 
ATACH-2 were treated with intravenous nicardipine, which 
A B
 Fig 1.  Haematoma expansion . A – non-contrasted CT brain showing right basal ganglia haematoma; B – CT brain 24 hours later showing haematoma 
expansion with peri-haematomal oedema, midline shift and intraventricular extension. CT = computerised tomography 
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has a weak antiplatelet effect, possibly negating the benefit 
achieved by BP reduction. 
 In conclusion, a target SBP of 140 mmHg is probably safe, 
while more intensive lowering of SBP to 120 mmHg does not 
appear to add further benefit. Secondary prevention of stroke 
with blood pressure control is crucial but is beyond the scope of 
this article. 20 
 Haemostatic therapy 
 The aim of haemostatic therapy is to prevent continued 
bleeding of the haematoma. The clinical approach 
depends on whether the patient has received proximal 
anticoagulation therapy; such patients have worse outcomes 
in part due to continued bleeding, thus warranting urgent 
reversal. 
 Vitamin K antagonist-related ICH 
 Vitamin K antagonists (VKA), such as warfarin, should be 
withheld and intravenous vitamin K 10 mg given immediately. 
Prothrombin complex concentrate (PCC) normalises INR 
more rapidly than fresh frozen plasma (FFP) and this should 
be given as soon as possible. In the recent INCH (intracranial 
haemorrhage related to vitamin K antagonists) trial, 4-factor 
PCC reversed INR to <1.2 within 3 hours in 67% (18 of 
27 patients) compared with FFP (9%, 2 of 23 patients) in 
sICH. 21 Protocols should be in place to reduce delay in giving 
PCC, including implementing point-of-care INR measurement 
and storage of PCC in emergency departments or hyperacute 
stroke units. 22 
 Novel oral anticoagulant-related ICH 
 Novel oral anticoagulants (NOACs), including dabigatran, 
rivaroxaban, apixaban and edoxaban, are widely used as an 
alternative to VKA. Idarucizumab, a reversal agent specific 
to dabigatran, is effective within minutes of administration 
and should be used in all cases of dabigatran-related sICH. 23 
Andexanet, a reversal agent for rivaroxaban, apixaban and 
edoxaban is not yet available. 24 Where an effective antidote is 
not available, NOACs-related sICH can be treated supportively 
with PCC, FFP or tranexamic acid. 25 
 Anti-platelet related ICH 
 Despite plausible physiological benefits of platelet transfusion 
in reducing the extent of ICH in patients taking anti-platelet 
agents, the PATCH (Platelet transfusion versus standard care 
after acute stroke due to spontaneous cerebral haemorrhage 
associated with antiplatelet therapy) trial reported that giving 
platelet transfusions was in fact harmful and should be 
avoided. 26 Among 97 patients who were randomised to receive 
platelet transfusion and 93 patients who received standard 
care, death and dependency was significantly higher in patients 
who received platelet transfusion (adjusted common odds 
ratio 2.05, 95% CI 1.18–3.·56; p = 0.0114). Forty patients (42%) 
who received platelet transfusion had serious adverse events 
 Table 1.  General management of patients with spontaneous intracerebral haemorrhage 
Section Recommendations 
General care/nursing 
care
All patients should be admitted to an acute stroke unit or intensive care unit. Frequent vital sign checks, 
neurological assessment and continuous cardiopulmonary monitoring (pulse oximetry, automated BP cuff and 
ECG telemetry) should be performed.
Airway protection Ventilation should be considered for patients with impending ventilator failure, at risk of aspiration, signs of 
raised intracranial pressure or brainstem dysfunction.
ICP monitoring ICP should be monitored in patients with IVH, hydrocephalus, signs of transtentorial herniation or GCS≤8 that 
were presumably caused by haematoma mass effect.
Maintenance of ICP of <20 mmHg and CPP of 50–70 mmHg is reasonable.
Blood pressure In patients with acute sICH presenting within 6 hours of symptom onset, blood pressure should be lowered to 
SBP<140 mmHg within 1 hour.
VTE prophylaxis Intermittent pneumatic compression should be used. Graduated compression stockings should be avoided.
Dysphagia screening Patients should be kept nil by mouth until a formal swallowing assessment is done.
Fever High grade fever of >38°C should be treated with paracetamol and/or tepid sponging.
Glucose Hypoglycaemia and hyperglycaemia should be treated. In treating hyperglycaemia, insulin should be used.
Intravenous fluid Avoid over-hydration. Avoid dextrose-containing fluid.
Seizure Patients with clinical seizure(s) should be treated with antiepileptic agent(s). Patients without seizure should 
not be prophylactically treated with antiepileptic agent(s).
Patients with altered conscious level and epileptic discharges detected on electroencephalography should be 
treated with antiepileptic agents.
DNAR order Early DNAR order should be avoided in the first few days as it may limit active medical treatment.
 BP = blood pressure; CPP = cerebral perfusion pressure; DNAR = do not attempt resuscitation; ECG = electrocardiogram; GCS = Glasgow Coma Scale; ICP = intracranial 
pressure; IVH = intraventricular haemorrhage; SBP = systolic blood pressure; sICH = spontaneous intracerebral haemorrhage; VTE = venous thromboembolism 
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compared with 28 patients (29%) who received standard 
care. 26 
 Non-antithrombotic related ICH 
 There is currently no haemostatic agent that is proven to limit 
haematoma expansion in non-anticoagulant related ICH. 27 The 
most widely researched agent, activated recombinant factor 
VIIa, did not improve clinical outcome or reduce haematoma 
size. 28 Ongoing trials are investigating efficacy of tranexamic 
acid in sICH. 29,30 
 Role of neurosurgery 
 Not all patients with sICH benefit from surgery. Several factors 
should be taken into consideration when deciding on surgery, 
including haematoma location, patient's prognostic factors, 
timing and type of surgery. 
 Cerebellar haemorrhage 
 Cerebellar haemorrhage may cause compression of the fourth 
ventricle (resulting in obstructive hydrocephalus) and of the 
brainstem leading to herniation syndrome. Therefore, posterior 
decompression should be performed in patients with cerebellar 
haematoma of >3 cm and those that result in hydrocephalus or 
 Table 2.  Causes of spontaneous intracerebral haemorrhage, investigations and characteristics 
Causes Investigations Characteristics 
Hypertensive arteriopathy MRI including T2 GRE 
or SWI sequence
Presence of deep-seated cerebral microbleeds, leukoaraiosis and lacunar infarctions 
is supportive.
Cerebral amyloid 
angiopathy
MRI including T2 GRE 
or SWI sequence
Apolipoprotein E 
(ε2 and ε4 alleles)
MRI: lobar haemorrhage, microhaemorrhages at cortico-subcortical junctions. 
Carrier of Apolipoprotein ε2 and ε4 alleles have higher risk of recurrent sICH.
Cavernoma MRI MRI: heterogeneous signal intensities on T1 and T2 with a hypointense 
surrounding rim. Typically described as ‘popcorn’ or ‘berry’ appearance.
Arteriovenous 
malformation
MRI, MRA, DSA MRA/DSA: dilated arteries feeding a nidus and multiple draining veins.
Intracranial aneurysm CTA, MRI, MRA, DSA Presence of subarachnoid haemorrhage. DSA is the gold standard in detecting 
aneurysm.
Cerebral venous 
thrombosis
CTV, MRV Clinical signs of increased intracranial pressure. Symmetrical haemorrhagic 
infarctions. Filling defect (flow void) in the venous system.
Dural arteriovenous fistula CTA, MRA, DSA Haematoma location near venous sinus and cortical veins.
Brain tumour/metastasis CECT/MRI 50% of patients with brain metastasis will have multiple lesions that may show 
contrast enhancement.
Anticoagulant History/coagulation 
profile
Prolongation of coagulation profile. In patients on NOACs, the presence of normal 
coagulation profile does not indicate absence of coagulopathy.
Thrombolysis agent History Diagnosis of prior ischaemic stroke or myocardial infarction requiring thrombolysis 
is usually evident.
Cocaine and 
sympathomimetic drugs
History
Urine cocaine levels
Elevated urine cocaine levels can be detected within 72 hours of cocaine use.
 CECT = contrast-enhanced computerised tomography; CTA = computerised tomography angiography; CTV = computerised tomography venography; DSA = digital 
subtraction angiography; GRE = gradient recall echo; MRA = magnetic resonance angiography; MRI = magnetic resonance imaging; MRV = magnetic resonance 
venography; NOAC = novel oral anticoagulants; SWI = susceptibility-weighted imaging 
brainstem compression. 31 Insertion of an intraventricular drain 
or ventriculostomy without decompression is insufficient. 17 
 Supratentorial haemorrhage 
 There is no evidence that routine surgery for all patients 
with supratentorial haemorrhage is beneficial. In the 
STICH (Surgical Treatment for Ischemic Heart Failure) 
trial, involving 1,033 patients with sICH, early surgery 
did not improve outcome. 32 However, there was apparent 
benefit in patients and those with superficial lobar 
haematoma. The subsequent STICH II (Surgical Trial in 
Lobar Intracerebral Hemorrhage) trial reported that early 
surgery non-significantly reduced mortality in patients with 
superficial lobar haematoma (<1 cm from surface) without 
intraventricular extension and Glasgow Coma Scale (GCS) 
score of >8. 33 A meta-analysis including STICH II and 
14 other trials concluded overall benefit for early surgery 
although this should be interpreted with caution because of 
significant heterogeneity between the trials. 33 
 Timing of surgery 
 Surgery performed within 8 hours from onset appears to be 
beneficial. 34 However, ultra-early surgery performed within 
4 hours from onset is not beneficial and might be harmful. 35 
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 Type of surgery 
 Craniotomy and evacuation of haematoma was the procedure 
most commonly performed on patients in large clinical trials. 
The decision to undertake craniotomy and evacuation of 
haematoma on a patient with supratentorial haemorrhage should 
be individualised with consideration of the following points: 
 >  patients with superfi cial lobar haemorrhage <1 cm from 
surface may benefi t, whereas patients with deep seated 
haemorrhage do not appear to benefi t 
 >  evacuation of haematoma should be considered for patients 
with intermediate GCS of 9–12; patients with poor GCS of 
<8 or fully alert are unlikely to benefi t. 
 On the other hand, decompressive craniectomy may be 
lifesaving in patients with coma, large haematoma with midline 
shift and medically intractable raised intracranial pressure 
based on case-control studies and case series. 17,36 In addition, 
when sICH is complicated with hydrocephalus, the placement 
of an external ventricular drain lowers intracranial pressure 
and may reduce mortality. 17,37 An external ventricular drain 
allows for monitoring of intracranial pressure. 
 Phase III studies testing minimally invasive surgery and 
intraventricular thrombolysis for intraventricular haemorrhage 
are ongoing and may change our approach in the near 
future. 38,39 
 Restarting antithrombotic therapy 
 In all cases of sICH (except if secondary to cerebral venous 
thrombosis, where anticoagulation should be instigated), 
antiplatelet therapy and anticoagulants should be withheld in 
the acute setting. 40 Thereafter, it is unclear whether and when 
antithrombotic therapy should be restarted. The decision 
to restart should be tailored to the individual after carefully 
considering the benefits of antithrombotic therapy against the 
risks of recurrent sICH. 
 Risk of recurrent ICH 
 Most rebleeding in sICH occurs in the first 24 hours. 
Subsequently, the annual risk of recurrent sICH is estimated 
to be 2–3%. 41 However, certain factors are associated with 
higher risk of recurrent sICH, including poorly controlled 
hypertension (three- to fourfold risk), 42 cerebral amyloid 
angiopathy (Fig  2 , up to 22% per year), 43 lobar haemorrhage 
(3–14% per year), 44 arteriovenous malformation (18% per year) 
and cerebral microbleeds on MRI (eightfold risk). 45 The risk 
of recurrent sICH increases three- to fivefold in patients taking 
VKA. 46 In addition, VKA is associated with larger haematomas 
and worse outcome. NOACs have been considered to have lower 
risk of recurrent sICH compared with VKA (relative risk of 
0.46). 47 As for antiplatelet therapy, there is conflicting evidence 
to whether it increases the risk of recurrent sICH. Some studies 
concluded that antiplatelet therapy increased the risk of 
recurrent sICH while others did not. 43 
 Risk of thromboembolism and protective effect of 
antithrombotic therapy 
 Prosthetic heart valves are highly thrombogenic and carry a 
4–8% annual risk of thromboembolism if not anticoagulated. 48 
VKA reduces the risk of thromboembolism by 75%. 49 NOACs 
carry a lower risk of bleeding than VKA but cannot be used 
in patients with prosthetic valves. A trial evaluating the use 
of dabigatran in prosthetic valves was terminated early due 
to excessive adverse events. 50 The annual risk of systemic 
thromboembolism in patients with atrial fibrillation varies 
between 1% and 15%, depending on CHA 2 DS 2 -VASc score. 
51 
The risk ranges from nearly 0% when CHA 2 DS 2 -VASc score is 
0 to 15% when the score is 9. Treatment with anticoagulation 
confers a 64% relative risk reduction of stroke. 52 
 There are no randomised controlled trials to guide decision 
making in restarting antithrombotic therapy in patients with 
prior sICH. One observational study of 1,752 patients with 
atrial fibrillation and ICH suggested an overall mortality 
benefit of restarting oral anticoagulation compared with 
antiplatelet therapy or no antithrombotics. 53 However, the 
study did not take into account the location of ICH, presence 
of microbleeds and other risk factors for recurrent ICH. 
Based on a decision analysis model, Eckman  et al suggested 
that anticoagulation should be avoided in all cases of lobar 
haemorrhage, but could be offered to deep haemorrhage if 
the risk of thrombotic events is >7% per year. 54 However, it 
is uncertain whether antiplatelet therapy should be offered 
when anticoagulation is deemed not suitable. In the face of 
clinical equipoise, enrolment into a clinical trial should be 
considered. One such trial in the UK is RESTART (REstart or 
STop Antithrombotics Randomised Trial), which is exploring 
the risk of recurrent sICH in patients who are given antiplatelet 
 Fig 2.  Cerebral amyloid angiopathy . Magnetic resonance susceptibility-
weighted imaging sequence showing superfi cial siderosis (white arrow) 
and cerebral microhaemorrhage (white arrow head), which are features 
 supportive of a diagnosis of cerebral amyloid angiopathy. 
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therapy. 55 Where this is not possible, the following points can 
be considered: 
 >  In patients with high risk of thromboembolism (prosthetic 
heart valves, high risk atrial fi brillation, high risk coronary 
artery disease) and low risk of recurrent sICH (deep 
haemorrhage, well controlled blood pressure) antithrombotic 
therapy should be considered. 
 >  Conversely, antithrombotics are discouraged in patients with 
high risk of recurrent sICH (cerebral amyloid angiopathy, 
presence of multiple microbleeds, lobar haemorrhage, 
uncontrolled hypertension). 
 >  For patients with high-risk non-valvular atrial fi brillation 
and a high risk of bleeding, percutaneous left atrial 
appendage occlusion may be considered for stroke 
prevention. Left atrial appendage occlusion is non-inferior to 
warfarin for stroke prevention in atrial fi brillation based on 
observational data and the PROTECT AF (Watchman Left 
Atrial Appendage System for Embolic Protection in Patients 
With Atrial Fibrillation) trial. 56,57 
 >  While NOACs have a lower bleeding risk than VKA, there 
is insuffi cient evidence to recommend using NOACs 
instead of VKA after anticoagulation-related sICH. An 
ongoing trial, APACHE AF (Apixaban versus Antiplatelet 
drugs or no antithrombotic drugs after anticoagulation-
associated intraCerebral HaEmorrhage in patients with 
Atrial Fibrillation) is exploring the rate of vascular death or 
non-fatal stroke in patients given apixaban compared with 
antiplatelet therapy or no antithrombotics after sICH. 58 
 >  The optimal timing to restart antithrombotic therapy is unclear. 
Observational studies reported that avoiding anticoagulation for 
7 days up to 10 weeks after sICH is safe. 59,60 ■
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